Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Resistant Hypertensive Subjects
NCT03089333Phase 4Completed
- Sponsor
- Universidade Estadual de Campinas
- Start
- Jul 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in resistant hypertension (RH) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Universidade Estadual de Campinas. Primary endpoint: Change in Systolic Blood Pressure at 12 weeks. Started Jul 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
resistant hypertension (RH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03089333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089333.